Company Overview

Nutriband Inc. is a pharmaceutical development company focused on the development of abuse‑deterrent transdermal drug delivery systems. The company operates within the biopharmaceutical and specialty pharmaceutical industries, with an emphasis on addressing prescription drug abuse, particularly opioids, through proprietary technology platforms. Its core value proposition is centered on enhancing patient safety while preserving therapeutic efficacy for approved pharmaceutical compounds.

The company’s primary business focus is the development of AVERSA™, a proprietary abuse‑deterrent technology designed to be incorporated into transdermal patches. Nutriband’s lead product candidate is AVERSA™ Fentanyl, which targets the large and established fentanyl transdermal patch market. Nutriband was founded in 2016 and has evolved from an early‑stage formulation company into a clinical‑stage pharmaceutical developer, advancing its technology through formulation development, manufacturing scale‑up, and regulatory preparation.

Business Operations

Nutriband operates through its wholly owned subsidiary 4P Therapeutics LLC, which houses the company’s pharmaceutical development activities and intellectual property. Revenue generation to date has primarily consisted of research and development arrangements and milestone‑based collaboration payments rather than commercial product sales, as the company’s products remain in the development stage.

The company’s operations are largely outsourced, leveraging third‑party contract development and manufacturing organizations for formulation development, clinical batch production, and regulatory support. A key operational partnership is with Kindeva Drug Delivery L.P., which provides expertise in transdermal patch manufacturing and commercialization support. Nutriband does not currently maintain large‑scale manufacturing facilities and instead follows a capital‑efficient, partnership‑driven operating model.

Strategic Position & Investments

Strategically, Nutriband is positioned to capitalize on heightened regulatory and societal demand for abuse‑deterrent opioid formulations. Its growth strategy centers on advancing AVERSA™ Fentanyl through regulatory approval and securing licensing or commercialization agreements with established pharmaceutical companies. The company has indicated that successful approval of its lead product could validate the broader application of the AVERSA™ platform across additional transdermal drugs.

Nutriband’s principal investment is in the continued development and regulatory advancement of its AVERSA™ technology portfolio. The company has not completed major acquisitions but has invested significantly in intellectual property development and patent protection. Its pipeline strategy focuses on expanding the application of AVERSA™ to other controlled substances delivered via transdermal systems, representing potential long‑term portfolio expansion.

Geographic Footprint

Nutriband is headquartered in the United States, with corporate offices in Florida. Its primary market focus is North America, particularly the U.S. pharmaceutical market, which represents the largest global market for prescription opioid therapies and abuse‑deterrent formulations.

While the company does not maintain extensive international operations, its strategic partnerships and manufacturing relationships extend into North America and Europe through third‑party service providers. Nutriband’s intellectual property strategy and regulatory planning are designed to support potential future expansion into additional international markets following U.S. regulatory approval.

Leadership & Governance

Nutriband is led by an executive team with experience in pharmaceutical development, regulatory strategy, and corporate governance. The leadership emphasizes capital efficiency, partnership‑driven development, and a focused approach to addressing unmet needs in drug abuse deterrence.

Key executives and leaders include:

• Gareth Sheridan – Chief Executive Officer
• David J. Nelson – Chief Financial Officer
• Jack Levis – Chairman of the Board
• Brian Lenz – Director

The company’s governance structure includes an independent board of directors overseeing strategy, risk management, and shareholder interests, consistent with U.S. public company standards.